Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Hemochromatosis subjects as allogeneic blood donors: a prospective study

View through CrossRef
BACKGROUND:  Persons with hemochromatosis constitute a plentiful and willing source of blood for transfusion. A program was established and evaluated for treating persons with hemochromatosis in a donor center and making their blood available for transfusion.STUDY DESIGN AND METHODS:  Phlebotomy therapy was performed free of charge regardless of whether subjects met criteria for allogeneic donation. A Hb level of 12.5 g per dL was used as the threshold for performing phlebotomy, and decreases in the MCV were used to guide the endpoints of therapy.RESULTS:  A total of 130 subjects were consecutively enrolled: 74 percent were homozygous for the C282Y mutation in the HFE gene, 76 percent met eligibility criteria for allogeneic donation, and 55 percent were previous blood donors. A median of 20 weekly or biweekly phlebotomies (range, 7‐99) were performed before the MCV reached the targeted endpoint of 3 percent below baseline, at which time the ferritin level was less than 30 µg per L and the transferrin saturation was less than 30 percent. The median phlebotomy interval necessary to keep the MCV at this level during maintenance therapy was 10 weeks. No incident seroconversions for agents of transfusion‐transmissible disease occurred during 1402 donations. All subjects testing positive for viral agents gave a prior history of deferrable risk. Twenty‐seven months after starting the program, hemochromatosis donors were contributing 14 percent of the RBC units collected for allogeneic use.CONCLUSIONS:  Hemochromatosis subjects can safely and significantly augment the allogeneic blood supply. Provision of phlebotomy therapy unrestricted by considerations of cost or suitability for donation can improve access to care and remove incentives for incomplete risk disclosure.
Title: Hemochromatosis subjects as allogeneic blood donors: a prospective study
Description:
BACKGROUND:  Persons with hemochromatosis constitute a plentiful and willing source of blood for transfusion.
A program was established and evaluated for treating persons with hemochromatosis in a donor center and making their blood available for transfusion.
STUDY DESIGN AND METHODS:  Phlebotomy therapy was performed free of charge regardless of whether subjects met criteria for allogeneic donation.
A Hb level of 12.
5 g per dL was used as the threshold for performing phlebotomy, and decreases in the MCV were used to guide the endpoints of therapy.
RESULTS:  A total of 130 subjects were consecutively enrolled: 74 percent were homozygous for the C282Y mutation in the HFE gene, 76 percent met eligibility criteria for allogeneic donation, and 55 percent were previous blood donors.
A median of 20 weekly or biweekly phlebotomies (range, 7‐99) were performed before the MCV reached the targeted endpoint of 3 percent below baseline, at which time the ferritin level was less than 30 µg per L and the transferrin saturation was less than 30 percent.
The median phlebotomy interval necessary to keep the MCV at this level during maintenance therapy was 10 weeks.
No incident seroconversions for agents of transfusion‐transmissible disease occurred during 1402 donations.
All subjects testing positive for viral agents gave a prior history of deferrable risk.
Twenty‐seven months after starting the program, hemochromatosis donors were contributing 14 percent of the RBC units collected for allogeneic use.
CONCLUSIONS:  Hemochromatosis subjects can safely and significantly augment the allogeneic blood supply.
Provision of phlebotomy therapy unrestricted by considerations of cost or suitability for donation can improve access to care and remove incentives for incomplete risk disclosure.

Related Results

[RETRACTED] Guardian Blood Balance –Feel the difference Guardian Blood Balance makes! v1
[RETRACTED] Guardian Blood Balance –Feel the difference Guardian Blood Balance makes! v1
[RETRACTED]Guardian Blood Balance Reviews (Works Or Hoax) Does Guardian Botanicals Blood Balance AU Really Works? Read Updated Report! Diabetes and Hypertension is such a health p...
Follow-up of 12,559 Unrelated Donors of Peripheral Blood Stem Cells or Bone Marrow
Follow-up of 12,559 Unrelated Donors of Peripheral Blood Stem Cells or Bone Marrow
Abstract Abstract 365 Donor follow-up is indicated to detect potential long-term risks for allogeneic stem cell donors. We sent a follow-up questionna...
Allogeneic Hematopoietic Stem Cell Transplant Versus Gene Therapy in Sickle Cell Disease: A Systematic Review
Allogeneic Hematopoietic Stem Cell Transplant Versus Gene Therapy in Sickle Cell Disease: A Systematic Review
BACKGROUND: Despite advancements in medical therapy and supportive care for sickle cell disease (SCD) over the last several decades, disease morbidity and mortality remain unaccept...
RHD Genotyping of Blood Donors May Avoid Anti-D Immunization.
RHD Genotyping of Blood Donors May Avoid Anti-D Immunization.
Abstract Antigen D compatible transfusion is standard practice in modern transfusion therapy, warranting proper antigen D typing in all blood donors. Blood group gen...
The blood‐donation experience: perceived physical, psychological and social impact of blood donation on the donor
The blood‐donation experience: perceived physical, psychological and social impact of blood donation on the donor
Background and Objectives This study aimed to investigate the impact and effects of blood donation on blood donors as perceived and reported by donors themselves.Materials and Meth...
Dysmyelopoiesis In Healthy Bone Marrow Donors
Dysmyelopoiesis In Healthy Bone Marrow Donors
Abstract Abstract 4006 Background: According to WHO, the recommended requisite percentage of cells manifesting dy...

Back to Top